Core Insights - Renaissance Investment Management's Q4 2025 "Large Cap Growth Strategy" underperformed compared to the S&P 500 and Russell 1000 Growth Index, with the S&P 500 gaining 2.7% during the quarter [1] - The broader market remained weak, with nearly 60% of Russell 1000 Growth constituents posting negative returns, despite a rally in equities for three consecutive quarters [1] - Portfolio performance was bolstered by holdings benefiting from AI infrastructure, semiconductor equipment, and resilient healthcare distribution trends, while declines were noted in financial technology, cloud software, media streaming, transportation, and communications equipment sectors [1] Company-Specific Insights - Cardinal Health, Inc. (NYSE:CAH) is highlighted as a key holding, distributing pharmaceuticals and medical products, with a one-month return of -8.33% and a market capitalization of approximately $48.76 billion [2] - Cardinal Health's stock traded between $120.72 and $233.60 over the last 52 weeks, closing at around $207.23 per share on March 24, 2026 [2]

Company Overview - Henry Schein, Inc. (HSIC) has a market cap of $8.5 billion and is a global healthcare distribution and solutions company headquartered in Melville, New York, serving healthcare professionals in over 30 countries [1] - The company is classified as a "mid-cap" stock, valued between $2 billion and $10 billion, and offers an integrated "one-stop-shop" ecosystem that combines a broad distribution network with software, financial services, and consulting [2] Financial Performance - For FY2025 Q4, Henry Schein reported total net sales of $3.4 billion, a year-over-year increase of 7.7%, and a non-GAAP net income growth of 12.6% to $1.34 [6] - Adjusted EBITDA for the quarter rose 7.8% from the previous year to $291 million, with Global Specialty Products sales increasing by 14.6%, driven by strong dental implant and endodontics sales [6] Stock Performance - HSIC shares have retreated 16.6% from their 52-week high of $89.29 and have declined 2.7% over the past three months, while the S&P 500 Index fell by 4.8% during the same period [3] - Over the past six months, HSIC stock has increased by 7.6%, outperforming the S&P 500's 1.1% increase, but has only climbed 7.3% over the past 52 weeks compared to the S&P 500's 16.1% return [5] - The stock has been trading above its 200-day moving average since November 2025 but has recently slipped below its 50-day moving average [5] Competitive Landscape - Rival Quest Diagnostics Incorporated (DGX) has outperformed HSIC stock, returning 4.6% over the past six months and 17.1% over the past 52 weeks [7] - DGX has a consensus rating of "Moderate Buy" from 16 analysts, with a mean price target of $89.78, representing a 20.6% premium to current levels [7]

Core Viewpoint - Britt Vitalone, CFO of McKesson, announced his retirement, marking a significant transition for the company and its leadership team [1] Company Overview - McKesson's investor relations and finance team members were present at the conference, indicating ongoing engagement with stakeholders [1] - The company has a strong track record under Britt Vitalone's leadership, highlighting his contributions to McKesson's success [1]

Core Insights - The session is part of the Leerink Global Healthcare Conference, focusing on healthcare technology distribution [1] - The management team from Cardinal Health is present, including the CFO and members of the Investor Relations team [1] Company Overview - Aaron Alt is introduced as the CFO of Cardinal Health, indicating a stable leadership position [1] - Matt Sims and David Frost are also part of the management team, highlighting the company's commitment to investor relations and strategic efforts [1]

Summary of Henry Schein Conference Call Company Overview - **Company**: Henry Schein - **Industry**: Healthcare distribution, specifically dental and medical supplies Key Points and Arguments Leadership Transition - Henry Schein has appointed Fred Lowery as the new CEO, marking the first leadership change since the first Bush administration, with Lowery being the fourth CEO in 94 years [2][3] - Lowery brings operational excellence and a fresh perspective, previously having a successful tenure at Thermo Fisher [3][4] Market Trends - The dental market shows signs of stabilization and potential improvement, with core dental market growth previously estimated at 2%-4% [6][7] - Henry Schein's sales growth in the fourth quarter exceeded market growth, attributed to aggressive customer relationship strategies and promotional partnerships [7][8] Equipment Sales - The equipment segment saw significant growth, driven by partnerships with manufacturers and exclusive promotions [8][12] - Growth in equipment sales is viewed as a bellwether for practitioners' confidence in investing in their practices, indicating potential expansion in dental services [12][13] Macro Economic Factors - Interest rates have some influence on equipment sales, but the correlation is not strong; access to care and unemployment rates are more critical indicators for market performance [15][16] - The company focuses on helping practices improve efficiency and patient throughput rather than solely discussing macroeconomic indicators with clients [16] Role of Dental Service Organizations (DSOs) - DSOs are crucial for both merchandise and equipment sales, with 25 of the 27 largest DSOs in the U.S. considering Henry Schein their primary distributor [19] - The growth of DSOs is outpacing the rest of the market, providing Henry Schein with opportunities to capture market share [19] Specialty Segment Growth - Henry Schein is positioned as a leading player in the implant and endodontic markets, with steady growth in these segments [28][30] - The company aims to expand its market share in implants, particularly through value implants that appeal to general practitioners [29][35] Technology and AI Integration - Henry Schein One is leveraging AI through a partnership with AWS to enhance its digital imaging and practice management solutions [37][38] - New products like Voice Notes and Image Verify aim to reduce administrative burdens and improve operational efficiency for practitioners [38][39] Value Creation Plan - The company is focused on a value creation plan expected to deliver $125 million in operating income improvement by the end of 2026 [47][48] - This plan emphasizes structural changes and resource optimization across the organization, differing from past grassroots restructuring efforts [52] Medical Business Expansion - Henry Schein is expanding its medical business, particularly in home healthcare, which is growing faster and more profitably than its core medical business [56] - The company is focusing on consumable merchandise rather than durable medical equipment (DME) for its Home Solutions business [58] Additional Important Insights - The company is committed to maintaining strategic relationships with DSOs to avoid transactional dynamics and focus on driving profitability for practices [23][24] - The specialty segment, particularly implants, is seen as a significant growth area, with a goal of increasing the contribution of high-margin products to over 50% of operating income by 2027 [34][35]

Company Overview - Cardinal Health is a global leader in healthcare services and products, operating in two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution [4] - The company delivers a wide range of pharmaceuticals and medical supplies to over 90% of U.S. hospitals and various healthcare facilities [4] Financial Performance - In the fiscal second quarter, Cardinal Health's sales increased by 19% to $65.6 billion, with earnings per share rising to $1.97 [5] - Analysts project a 16% annual growth in EPS for the next five years, highlighting the company's strong position in the healthcare supply chain [5] Market Position and Demand - Cardinal Health's business model benefits from inelastic demand for prescription drugs and medical supplies, making it resilient during economic downturns [8] - The company manages 40,000 pharmaceutical deliveries daily, ensuring a steady supply to hospitals and pharmacies [5] Dividend and Shareholder Returns - Cardinal Health has a long history of rewarding shareholders, having paid dividends for over four decades and increased its payout for 31 consecutive years, qualifying it as a Dividend Aristocrat [7] - The current annual dividend is $2.04 per share, yielding 0.93%, with a conservative payout ratio of approximately 30% [7] Investment Outlook - In the current economic environment characterized by stagflation, Cardinal Health is viewed as a strong investment due to its defensive characteristics and essential demand [3][8]

Leadership Changes - Delta Air Lines CFO Dan Janki will transition to the role of Chief Operating Officer, with Erik Snell succeeding him as CFO [2] - L3Harris Technologies appointed Ken Sharp as CFO, effective March 16, replacing Ken Bedingfield, who will remain president of the Missile Solutions segment [3] - McKesson has named Kenny Cheung as its new CFO, effective May 29, replacing Britt Vitalone, who is retiring after 20 years [4] - Sysco appointed Brandon Sewell as interim CFO to replace Kenny Cheung, effective March 6 [5] - Thomson Reuters has selected Gary Bischoping as its new CFO, effective May 8, succeeding Mike Eastwood, who is retiring [6] Background of New CFOs - Dan Janki joined Delta Air Lines in July 2021 after a 29-year career at GE [2] - Ken Sharp previously served as CFO at Peraton and has held CFO roles at DXC Technology and Northrop Grumman [3] - Kenny Cheung was CFO at Sysco for three years before joining McKesson and has prior experience at Hertz [4] - Brandon Sewell has been with Sysco since 2014, serving as senior vice president and CFO of its U.S. business [5] - Gary Bischoping was a partner at Hellman & Friedman and has held CFO positions at Finastra and Varian Medical Systems [6] Strategic Implications - The Department of Defense has made a $1 billion anchor investment to support the spin-off of L3Harris's Missile Solutions segment, indicating significant strategic moves in the defense sector [3] - McKesson is planning a separation of its Medical Surgical Solutions, with the outgoing CFO transitioning to a strategic adviser role [4] - Thomson Reuters will see Mike Eastwood transition to chairman of the board of the Thomson Reuters Foundation, indicating a shift in leadership focus [6]

Core Insights - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market over the next 30 days, using an alphabetic rating system from A to F based on value, growth, and momentum qualities [2][10]. Value Score - The Value Style Score focuses on identifying stocks that are undervalued relative to their true worth, utilizing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow to highlight attractive investment opportunities [3]. Growth Score - The Growth Style Score emphasizes a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable long-term growth [4]. Momentum Score - The Momentum Style Score assists investors in capitalizing on price trends, using metrics like one-week price changes and monthly earnings estimate changes to determine optimal entry points for stocks [5]. VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores into a single metric, helping investors find stocks with the best overall characteristics for value, growth forecasts, and momentum [6]. Zacks Rank - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.86% since 1988, significantly outperforming the S&P 500 [7][8]. Stock Selection Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 that also possess Style Scores of A or B, while stocks with a 3 (Hold) rank should also have high Style Scores to ensure potential upside [10][11]. Company Spotlight: Henry Schein Inc. - Henry Schein Inc., based in Melville, NY, is a leading distributor of healthcare products and services, operating in 33 countries and serving various healthcare practitioners and institutions [12]. - Currently rated 3 (Hold) by Zacks, Henry Schein has a VGM Score of A and a Growth Style Score of A, with a projected year-over-year earnings growth of 6.6% for the current fiscal year [12][13]. - Recent upward revisions in earnings estimates by analysts indicate a positive outlook, with the Zacks Consensus Estimate increasing by $0.03 to $5.30 per share, and an average earnings surprise of +2.1% [13].

Core Insights - McKesson Corporation is a leading player in global healthcare distribution, connecting biopharma manufacturers, providers, pharmacies, and patients [1] - The company has a market capitalization of approximately $120.9 billion, indicating its significant presence in the healthcare distribution sector [2] Stock Performance - MCK stock reached a 52-week high of $987.37 in February, with a 11.7% increase over the past three months, outperforming the Nasdaq Composite, which fell by 2.4% [3] - Over the last 52 weeks, MCK stock has surged by 59% and is up 20.4% year-to-date, while the Nasdaq has advanced by 22.2% but declined by 2.5% year-to-date, showcasing McKesson's relative outperformance [5] - The stock has been trading above its 50-day moving average of $865.65 and its 200-day moving average of $776.06 since April 2025, indicating a strong technical structure [5] Financial Performance - In fiscal Q3 2026, McKesson reported revenue of $106.2 billion, an 11.4% year-over-year increase, meeting analyst expectations [7] - Adjusted EPS rose by 16.3% to $9.34, exceeding the Street's estimate of $9.27, reflecting strong financial performance [7] - Growth was driven by strong oncology performance, expanding biopharma services, and continued momentum in North American pharmaceutical distribution [8] - Management raised its full-year non-GAAP earnings outlook, projecting a growth of 17% to 19% compared to the previous year [8] Competitive Positioning - Compared to rival Cencora, Inc., which gained 49.5% over the past 52 weeks and is up 10.2% year-to-date, McKesson has outperformed in both longer-term and year-to-date measures [9]

Core Insights - Henry Schein reported its highest sales growth in 15 quarters, with fourth-quarter global sales reaching $3.4 billion, up 7.7% year over year, driven by strong performance across various segments [2][4][6]. Financial Performance - The company reported a fourth-quarter GAAP operating margin of 4.76%, down 10 basis points from the prior year, while the non-GAAP operating margin was 7.42%, remaining relatively flat year over year [1]. - Fourth-quarter GAAP net income was $101 million, or $0.85 per diluted share, compared to $94 million, or $0.74 per diluted share, in the prior-year period. Non-GAAP net income was $160 million, or $1.34 per diluted share, up from $149 million, or $1.19 per diluted share [7]. - Adjusted EBITDA for the fourth quarter was $291 million, an increase from $270 million, representing an 8.4% growth [7]. Segment Performance - Global specialty products saw sales growth of 14.6%, driven by strong performance in implants and biomaterials, with double-digit growth in value implants [10]. - Global technology sales grew 8.4%, supported by practice management software and significant growth in Dentrix Ascend, which surpassed 11,000 subscribers [11]. - The global distribution and value-added services group delivered 7.0% sales growth, with U.S. dental merchandise sales growing by 3.6% and U.S. dental equipment sales growing by 10.6% [8][9]. Leadership Transition - Fred Lowery will officially join as CEO next week, with a focus on a 100-day "listening tour" to validate existing initiatives and engage with stakeholders [3][6]. - Stanley Bergman will remain as Chairman of the Board, emphasizing Lowery's experience in scaling businesses through acquisitions and organic growth [4][6]. Strategic Initiatives - The company expects over $200 million of operating income improvement through cost savings and incremental gross margin opportunities, with an annual run-rate improvement of over $125 million by the end of 2026 [13]. - Henry Schein repurchased 2.8 million shares for $200 million at an average price of $71.10 per share, ending the year with approximately $780 million remaining under its authorization [14]. 2026 Outlook - For 2026, Henry Schein guided to sales growth of 3% to 5% and non-GAAP diluted EPS of $5.23 to $5.37, representing 5% to 8% growth compared to 2025 [15]. - The guidance assumes stable dental and medical end markets and consistent foreign exchange rates [15][16].